I-SAVE study: Impact of sedation, analgesia, and delirium protocols evaluated in the Intensive Care Unit: An economic evaluation;Estudio I-SAVE: Impacto de los Protocolos de Sedación, Analgesia y Delirio eValuados en la Unidad de Cuidados Intensivos: Una Evaluación Económica

Annals of Pharmacotherapy

Volumn 46, Issue 1, 2012, Pages 21-28

  Awissi, Don Kelena ^a   Bégin, Cindy ^a   Moisan, Julie ^b   Lachaine, Jean ^c   Skrobik, Yoanna ^a  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Analgesia; Cost analysis; Critical care; Delirium; Intensive care; Pharmacoeconomics; Sedation

Indexed keywords

ALPRAZOLAM; CELECOXIB; CODEINE; DIAZEPAM; FENTANYL; HALOPERIDOL; HYDROMORPHONE; INDOMETACIN; LEVOMEPROMAZINE; LORAZEPAM; MIDAZOLAM; MORPHINE; NAPROXEN; NICOTINE; OLANZAPINE; OXAZEPAM; OXYCODONE; PARACETAMOL; PETHIDINE; PROPOFOL; ROFECOXIB;

ADULT; ANALGESIA; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL PROTOCOL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DELIRIUM; ECONOMIC EVALUATION; FEMALE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NUMERIC RATING SCALE; PRIORITY JOURNAL; RICHMOND AGITATION AND SEDATION SCORING; SEDATION;

ANALGESIA; ANALGESICS; APACHE; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; DEEP SEDATION; DELIRIUM; HUMANS; HYPNOTICS AND SEDATIVES; INTENSIVE CARE; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RESPIRATION, ARTIFICIAL;

EID: 84855690834     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q284     Document Type: Article

References (20)

1. Canadian Institute for Health Information. National health expenditure trends 1975-2004. Ottawa, Ontario, 2004.
2. Adhikari N, Sibbald W. The large cost of critical care: realities and challenges. Anesth Analg 2003;96:311-4.
3. PricewaterhouseCoopers, 2010. The price of excess: identifying waste in health care spending. www.pwc.com/healthindustries (accessed 2011 Dec 15).
4. Jacobs P, Noseworthy TW. National estimates of intensive care utilization and costs: Canada and the United States. Crit Care Med 1990;18:1282-6.
5. Noseworthy TW, Konopad E, Shustack A, Johnston R, Grace M. Cost accounting of adult intensive care: methods and human and capital inputs. Crit Care Med 1996;24:1168-72.
6. Weber RJ, Kane SL, Oriolo VA, Saul M, Skledar SJ, Dasta JF. Impact of intensive care unit (ICU) drug use on hospital costs: a descriptive analysis, with recommendations for optimizing ICU pharmacotherapy. Crit Care Med 2003;31(1 suppl):S17-24. DOI 10.1097/01.CCM.0000042471.92011.8E
7. Ouimet S, Kavanagh BP, Gottfried SB, Skrobik Y. Incidence, risk factors and consequences of ICU delirium. Intensive Care Med 2007;33:66-73. DOI 10.1007/s00134-006-0399-8
8. Pandharipande P, Shintani A, Peterson J, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology 2006;104:21-6. DOI 00000542-200601000-00005
9. Sessler CN, Pedram S. Protocolized and target-based sedation and analgesia in the ICU. Crit Care Clin 2009;25:489-513. DOI 10.1016/j.ccc.2009.03.001
10. Skrobik Y, Ahern S, Leblanc M, Marquis F, Awissi DK, Kavanagh BP. Protocolized intensive care unit management of analgesia, sedation, and delirium improves analgesia and subsyndromal delirium rates. Anesth Analg 2010;111:451-63. DOI 10.1213/ANE.0b013e3181d7e1b8
11. Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med 2002;166:1338-44. DOI 10.1164/rccm.2107138
12. Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA 2003;289:2983-91. DOI 10.1001/jama.289.22.2983
13. Bergeron N, Dubois MJ, Dumont M, Dial S, Skrobik Y. Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med 2001;27:859-64.
14. Anis AH, Wang XH, Leon H, Hall R. Economic evaluation of propofol for sedation of patients admitted to intensive care units. Anesthesiology 2002;96:196-201.
15. Dasta JF, Kane-Gill S. Pharmacoeconomics of sedation in the ICU. Crit Care Clin 2009;25:571-83. DOI 10.1016/j.ccc.2009.03.002
16. Mascia MF, Koch M, Medicis JJ. Pharmacoeconomic impact of rational use guidelines on the provision of analgesia, sedation, and neuromuscular blockade in critical care. Crit Care Med 2000;28:2300-6.
17. Devlin JW, Holbrook AM, Fuller HD. The effect of ICU sedation guidelines and pharmacist interventions on clinical outcomes and drug cost. Ann Pharmacother 1997;31:689-95.
18. MacLaren R, Plamondon JM, Ramsay KB, Rocker GM, Patrick WD, Hall RI. A prospective evaluation of empiric versus protocol-based sedation and analgesia. Pharmacotherapy 2000;20:662-72.
19. Dasta JF, Kane-Gill SL, Pencina M, et al. A cost-minimization analysis of dexmedetomidine compared with midazolam for long-term sedation in the intensive care unit. Crit Care Med 2010;38:497-503. DOI 10.1097/CCM.0b013e3181bc81c9
20. Cox CE, Reed SD, Govert JA, et al. Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation. Crit Care Med 2008;36:706-14. DOI 10.1097/CCM.0B013E3181544248